Trials / Conditions / Metastatic HER2-Negative Breast Carcinoma

Metastatic HER2-Negative Breast Carcinoma

16 registered clinical trials studyying Metastatic HER2-Negative Breast Carcinoma — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Horm NCT07112053	University of Washington	Phase 2
Recruiting	Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer NCT06525766	Mayo Clinic	Phase 2
Withdrawn	Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Tre NCT06590558	National Cancer Institute (NCI)	Phase 1
Terminated	Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positiv NCT05554354	National Cancer Institute (NCI)	Phase 2
Recruiting	Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negat NCT06179303	University of Washington	Phase 2
Withdrawn	Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial NCT05967286	National Cancer Institute (NCI)	Phase 2
Completed	Tka Assay for CDK4/6i NCT06572800	Yale University	N/A
Recruiting	Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy NCT05770531	Vanderbilt-Ingram Cancer Center	Phase 2
Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377	National Cancer Institute (NCI)	Phase 2
Recruiting	UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases NCT05535413	Hunan Cancer Hospital	Phase 1 / Phase 2
Withdrawn	Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Ca NCT05244434	City of Hope Medical Center	N/A
Recruiting	Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases NCT04647916	SWOG Cancer Research Network	Phase 2
Withdrawn	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520	Pamela Munster	Phase 1
Active Not Recruiting	Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel NCT04090398	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cance NCT03939897	National Cancer Institute (NCI)	Phase 1